.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
US Army
Federal Trade Commission
QuintilesIMS
Cerilliant
Moodys
Baxter
Boehringer Ingelheim
Mallinckrodt
Cantor Fitzgerald

Generated: December 15, 2017

DrugPatentWatch Database Preview

Rucaparib camsylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for rucaparib camsylate and what is the scope of rucaparib camsylate patent protection?

Rucaparib camsylate
is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and twenty-six patent family members in fifty-two countries and twelve supplementary protection certificates in eleven countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate

US Patents:8
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 18
Drug Prices:see low prices
DailyMed Link:rucaparib camsylate at DailyMed

Pharmacology for rucaparib camsylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-001Dec 19, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-003May 1, 2017RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Clovis Oncology IncRUBRACArucaparib camsylateTABLET;ORAL209115-002Dec 19, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: rucaparib camsylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,169,235Phthalazinone derivatives► Subscribe
6,977,298 Tricyclic inhibitors of poly(ADP-ribose) polymerases► Subscribe
9,566,276Phthalazinone derivatives► Subscribe
8,912,187Phthalazinone derivatives► Subscribe
7,662,818Phthalazinone derivatives► Subscribe
7,981,889Phthalazinone derivatives► Subscribe
7,449,464Phthalazinone derivatives► Subscribe
7,429,578Tricyclic inhibitors of poly(ADP-ribose) polymerases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: rucaparib camsylate

Country Document Number Estimated Expiration
Norway331807► Subscribe
South Africa200105399► Subscribe
Ukraine75034► Subscribe
Norway334610► Subscribe
South Korea101138471► Subscribe
Japan2006519827► Subscribe
Japan5848728► Subscribe
European Patent Office2305221► Subscribe
Czech Republic20012443► Subscribe
Slovakia287338► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: RUCAPARIB CAMSYLATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015016,C1633724Lithuania► SubscribePRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216
90019-4Sweden► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REG. NO/DATE: EU/1/14/959 20141218
00726Netherlands► SubscribePRODUCT NAME: OLAPARIB, EN ZOUTEN EN; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
500012Hungary► SubscribePRODUCT NAME: OLAPARIB
/2015Austria► SubscribePRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216
0150012 00136Estonia► SubscribePRODUCT NAME: OLAPARIIB;REG NO/DATE: EU/1/14/959 18.12.2014
2015016Lithuania► SubscribePRODUCT NAME: OLAPARIBUM; REGISTRATION NO/DATE: EU/1/14/959 20141216
C0022France► SubscribePRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
3 50005-2015Slovakia► SubscribePRODUCT NAME: OLAPARIB; REGISTRATION NO/DATE: EU/1/14/959 20141218
15/016Ireland► SubscribePRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
US Department of Justice
Novartis
Baxter
Deloitte
Queensland Health
Dow
Chubb
Mallinckrodt
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot